Issue

Vol. 64 No. 13: Issue 13

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Inhibitory effects of various solvent extracts from Rhamnus frangula leaves on some inflammatory and metabolic enzymes

https://doi.org/10.14715/cmb/2018.64.13.11
Abir Ben Bacha
Biochemistry Department, Science College, King Saud University, P.O Box 22452, Riyadh 11495, Saudi Arabia
Ikram Jemel
Laboratory of Plant Biotechnology Applied to Crop Improvement, Faculty of Science of Sfax, University of Sfax, Sfax 3038, Tunisia
Ramesa Shafi Bhat
Biochemistry Department, Science College, King Saud University, P.O Box 22452, Riyadh 11495, Saudi Arabia
Mona Awad Onizi
Biochemistry Department, Science College, King Saud University, P.O Box 22452, Riyadh 11495, Saudi Arabia

Corresponding Author(s) : Abir Ben Bacha

aalghanouchi@ksu.edu.sa

Cellular and Molecular Biology, Vol. 64 No. 13: Issue 13

Abstract

Many enzymes are involved in numerous pathologies which are related to metabolic reactions and inflammatory diseases such as pancreatic lipase, α-amylase, α-glucosidase and xanthine oxidase and secreted phospholipases A2 (Group IIA, V and X), respectively. Therefore, inhibiting these enzymes offer the potential to block production of more inflammatory substances and decrease the risk factors for cardiovascular diseases. The purpose of this study was to investigate some potent, bioavailable and selective inhibitors of some catalytic proteins implicated to metabolic syndrome and their antioxidant effects from various solvent extracts of R. frangula leaves. The anti-inflammatory, obesity, diabete and XO potentials were evaluated through analyses of inhibition activities of corresponding metabolites.The water extract exhibited an important inhibitory effect on human, dromedary and stingray sPLA2-G IIA achieved an IC50 of 0.16±0.06, 0.19±0.05 and 0.07±0.01 mg/mL, respectively. Likewise, the same fraction demonstrated the highest pancreatic lipase inhibitory activity using two different substrates. Indeed, 50% of dromedary pancreatic lipase inhibition was demonstrated for 5 min and 15 min using olive oil and TC4 substrates, respectively. Besides, it was established that methanolic extract had more effective inhibitory lipase activity than ORLISTAT used as a specific inhibitor of gastric, pancreatic and carboxyl ester lipase for treating obesity, with an IC50 of 5.51±0.27 and 91.46±2.3 µg/mL, respectively. In the case of α-amylase, α-glucosidase and xanthine oxidase, the crude methanolic extract showed a potential inhibitory effect with an IC50 of 45±3.45, 3±0.15 and 27±1.71 µg/mL, respectively. Conclusively, R. frangula leaves extracts showed a potential value of some sPLA2, some metabolic enzymes and XO inhibitors as anti-inflammatory and metabolic syndrome drugs.

Keywords

R. frangula leaves Metabolic syndrome sPLA2 Pancreatic lipase α-amylase α-glucosidase Xanthine oxidase Inhibition.
Ben Bacha, A., Jemel, I., Bhat, R. S., & Onizi, M. A. (2018). Inhibitory effects of various solvent extracts from Rhamnus frangula leaves on some inflammatory and metabolic enzymes. Cellular and Molecular Biology, 64(13), 55–62. https://doi.org/10.14715/cmb/2018.64.13.11
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Nevalainen TJ, Eerola LI, Rintala E, Laine VJ, Lambeau G, Gelb MH. Time-resolved fluoroimmunoassays of the complete set of secreted phospholipases A2 in human serum. Biochim. Biophys. Acta. 2005;1733:210-223.
  2. Lambeau G and Gelb MH. Biochemistry and Physiology of Mammalian Secreted Phospholipases A2. Annu. Rev. Biochem. 2008;77:495-520.
  3. Prunzanski W, Vadas P, Browning J. Secretory non-pancreatic group II phospholipase A2: role in physiologic and inflammatory processes. J. Lipid. Mediat. 1993;8:161-67.
  4. Duchez AC, Boudreau LH, Naika GS, Bollinger J, Belleannée C, Cloutier N, et al. Platelet microparticles are internalized in neutrophils via the concerted activity of 12-lipoxygenase and secreted phospholipase A2-IIA. Proc Natl Acad Sci U S A. 2015;112(27): E3564-73.
  5. Arbibe L, Koumanov K, Vial D, Rougeot C, Faure G, Havet N, et al. Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type –II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction. J.Clin. Invest. 1998;102:1152-1160.
  6. Boilard E, Lai Y, Larabee K, Balestrieri B, Ghomashchi F, Fujioka D, et al. A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis. EMBO Mol Med. 2010;2(5):172-87.
  7. FitzGerald GA. Cox-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat. Rev.Drug Discov. 2003; 2: 879-890.
  8. Vane JR. Biomedicine. Back to an aspirin a day? Science. 2002; 296:474
  9. Coulthard LG, Costello J, Robinson B, Shiels IA, Taylor SM, Woodruff TM. Comparative efficacy of a secretory phospholipase A2 inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis. Arthritis Res Ther. 2011;13:R42.
  10. Bulas J, Ilcí­k M, Kozlí­ková K, Murí­n J. Risk profile of hypertensive patients. Vnitr Lek. 2010;56:832-7.
  11. Murray K. Burkard T. Hyperuricemia, gout and cardiovascular diseases. Ther Umsch. 2016;73:141-6.
  12. Lopes Galeno DM, Carvalho RP, Boleti AP, Lima AS, Oliveira-de-Almeida PD, Pacheco CC, et al. Extract from Eugenia punicifolia is an antioxidant and inhibits enzymes related to metabolic syndrome. Appl Biochem Biotechnol. 2014;172:311-24.
  13. Hadavary P, Lengsfeld H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochemical Journal. 1988;256:357-361.
  14. Hauptman JB, Jeunt FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). American Journal of Clinical Nutrition. 1992; 55:309-313.
  15. Drent ML, Larson I, William-Olsson T, Quaade F, Czubayko F, Von Bergmannk et al. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. International Journal of Obesity. 1995; 19:221-226.
  16. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352:167-172.
  17. Zhu X, Yang L, Xu F, Lin L, Zheng G. Combination therapy with catechins and caffeine inhibits fat accumulation in 3T3-L1 cells. Exp Ther Med. 2017;13:688-694.
  18. McCue P, Kwon YI, Shetty K. Anti-diabetic and anti-hypertensive potential of sprouted and solid-state bioprocessed soybean. Asia Pac J Clin Nutr. 2005;14:145-52.
  19. Azad SB, Ansari P, Akter S, Hossain SM, Azam S, Archi FF, et al. Anti-hyperglycemic activity of Moringa oleifera is partly mediated by carbohydrase inhibition and glucose-fiber binding. Biosci Rep. 2017; doi: BSR20170059.
  20. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabtes: a retrospective cohort study. Diabetes Care. 2003;26:2983-2989.
  21. Lin CC, Huang PC, Lin JM. Antioxidant and hepatoprotective effects of Anoectochilus formosanus and Gynostemma pentaphyllum. The American Journal Chinese Medicine. 2000; 28:87-96.
  22. Heber D, Seeram N, Wyatt H, Henning SM, Zhang Y, Ogden LG et al. Safety and antioxidant activity of a pomegranate ellagitannin-enriched polyphenol dietary supplement in overweight individuals with increased waist size. Journal of Agricultural and Food Chemistry. 2007;55:1005-10054.
  23. Bove M, Cicero AF, Veronesi M, Borghi C. An evidence-based review on urate-lowering treatments: implications for optimal treatments of chronic hyperuricemia. Vasc Health Risk Manag. 2017;13:23-28.
  24. Manojlovic NT, Solujic S, Sukdolak S, Milosev M. Antifungal activity of Rubia tinctorum, Rhamnus frangula and Caloplaca cerina. Fitoterapia. 2005;76:244-6.
  25. Singer AG, Ghomashchi F, Le Calvez C, Bollinger J, Bezzine S, Rouault M, et al. Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J Biol Chem. 2002;277:48535–48549.
  26. Mejdoub H, Reinbolt J, Gargouri Y. Dromedary pancreatic lipase: Purification and structural properties. Biochim Biophys Acta. 1994;1213:119–26.
  27. Ben Bacha A, Gargouri Y, Bezzine S, Mejdoub H. Purification and biochemical characterization of phospholipase A2 from dromedary pancreas. Biochim. Biophys. Acta. 2006;1760:1202-1209.
  28. Ben Bacha A, Karray A, Bouchaala E, Gargouri Y, Ben Ali Y. Purification and biochemical characterization of pancreatic phospholipase A2 from the common stingray Dasyatispastinaca. Lipids Health Dis. 2011;10:32–39.
  29. Ben Bacha A, Al-Daihan SK, Mejdoub H. Purification, characterization and antibacterial activities of phospholipase A2 from the dromedary intestine. Int. J. Biol. Macromol. 2013;57: 156–164.
  30. Ben Bacha A, Daihan SK, Moubayed NM, Mejdoub H. Purification and characterization of a new organic-solvent-tolerant sPLA2-IIA from common stingray intestine. Indian J. Biochem. Biophys. 2013;50:186-195.
  31. De Araújo AL, Radvanyi F. Determination of phospholipase A2 activity by a colorimetric assay using a pH indicator. Toxicon. 1987;25:1181-1188.
  32. Gargouri Y, Chahinian H, Moreau H, Ransac S, Verger R. Inactivation of pancreatic and gastric lipases by THL and C12:0-TNB: a kinetic study with emulsified tributyrin. Biochimica and Biophysica Acta. 1991;1085:322-328.
  33. Gargouri Y, Cudrey C, Mejdoub H, Verger R. Inactivation of human pancreatic lipase by 5-dodecyldithio-2-nitrobenzoic acid. European Journal of Biochemistry. 1992;204:1063-1067.
  34. Subranian R, Asnawi MZ, Sadikun A. In vitro alpha-glucosidase and alpha-amylase enzyme inhibitory effects of Andrographis paniculata extract and andrographolide. Acta. Biochimica Polonica. 2008;55:8896-8907.
  35. Andrade-Cetto A, Becerra-Jiménez J, Cardenas-Vazquez R. Alfa-glucosidase-inhibiting activity of some Mexican plants used in the treatment of type 2 diabetes. Journal of Ethnopharmacology. 2008;116:27-32.
  36. Bondet V, Brand-Williams W, Berset C. Kinetic and mechanisms of antioxidant activity using DPPF free radical method. Lebensmittel-Wissenschaft Technologie Food Sci Technol. 30 (1997) 609–615
  37. Cupillard L, Mulherkar R, Gomez N, Kadam S, Valentin E, Lazdunski M, et al. Both group IB and group IIA secreted phospholipases A2 are natural ligands of the mouse 180-kDa M-type receptor. J Biol Chem. 1999;274:7043-51.
  38. Richmond BL, Boileau AC, Zheng S, Huggins KW, Granholm NA, et al. Compensatory phospholipid digestion is required for cholesterol absorption in pancreatic phospholipase A(2)-deficient mice. Gastroenterology. 2001;120:1193-202.
  39. Huggins KW, Boileau AC, Hui DY. Protection against diet-induced obesity and obesity- related insulin resistance in Group 1B PLA2-deficient mice. Am J Physiol Endocrinol Metab. 2002;283:E994-1001.
  40. Bradley JD, Dmintrienko AA, Kivitz AJ, Gluck OS, Weaver AL, et al. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol. 2005;32:417-23.
  41. Schewe M, Franken PF, Sacchetti A, Schmitt M, Joosten R, Böttcher R, et al. Secreted Phospholipases A2 are intestinal Stem Cell Niche Factors with Distinct Roles in Homeostasis, Inflammation, and Cancer. Cell Stem Cell. 2016;19:38-51.
  42. Murakami M, Kudo I. New phospholipase A(2) isozymes with a potential role in atherosclerosis. Curr Opin Lipidol. 2003;14:431-36.
  43. Rosengren B, Jonsson-Rylander AC, Peilot H, Camejo G, Hurt-Camejo E. Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis. Biochim Biophys Acta. 2006;1761:1301-8.
  44. Kimura-Matsumoto M, Ishikawa Y, Komiyama K, Tsuruta T, Murakami M, et al. Expression of secretory phospholipase A2s in human atherosclerosis development. Atherosclerosis. 2008 ;196:81-91.
  45. Ait-Oufella H, Herbin O, Lahoute C, Coatrieux C, Loyer X, Joffre J, et al. Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol. 2013;33:466-73.
  46. Hurt-Camejo E, Camejo G, Peilot H, Oorni K, Kovanen P. Phospholipase A(2) in vascular disease. Circ Res. 2001;89:298-304.
  47. Karabina SA, Gora S, Atout R, Ninio E. Extracellular phospholipases in atherosclerosis. Biochimie. 2010;92:594-600.
  48. Juhel C, Arnaud M, Pafumi Y, Rosier C, Vandermander J, Lairon D. Green tea extract (AR25) inhibits lipolysis of triglycerides in gastric and duodenal medium in vitro. Journal of Nutritional Biochemistry. 2000;11:45-51.
  49. Wang, SM, Huang AH. Inhibitors of lipase activities in soybean and other oil seeds. Plant Physiology. 1984;76:929-934.
  50. Gargouri Y, Julien R, Pieroni G, Verger R, Sarda L. Studies on the inhibition of pancreatic and microbial lipases by soybean proteins. Journal of Lipid Research. 1984;25: 1214-1221.
  51. Ben Rebah F, Smaoui S, Frikha F, Gargouri Y, Miled N: Inhibitory effects of Tunisian marine algal extracts on digestive lipases. Appl Biochem Biotechnol. 2008;151:71-79.
  52. Yang Hee Jo, Seon Beom Ki, Qing Liu, Seon-Gil Do, Bang Yeon Hwang, Mi Kyeong Lee. Comparison of pancreatic lipase inhibitory isoflavonoids from unripe and ripe fruits of Cudrania tricuspidata. PLoS One. 2017;12:e0172069.
  53. Jemel I, Fendri A, Gargouri Y, Bezzine S. Kinetic properties of dromedary pancreatic lipase: A comparative study on emulsified and monomolecular substrate. Colloids and Surfaces B: Biointerfaces. 2009;70:238-242.
  54. Shobana S, Sreerama YN, Malleshi NG. Composition and enzyme inhibitory properties of finger millet (Eleusine Coracana L) seed coat phenolics: Mode of inhibition of alpha-glucosidase and pancreatic amylase. Food Chem. 2009;115:1268-73.
  55. Teng H, Chen L. α-Glucosidase and α-amylase inhibitors from seed oil: a review of liposoluble substance to treat diabetes. Crit Rev Food Sci Nutr. 2016; 6:0.
  56. Ahmed F, Chandra JN, Manjunath S. Acetylcholine and memory-enhancing activity of Ficus racemosa bark. Pharmacognosy Res. 2011;3:246-9.
  57. Hung H.C, Joshipura K.J, Jiang R., Hu F. B., Hunter D., Smith-Warner SA et al. Fruit and vegetable intake and risk of major chronic disease. Journal of the National Cancer Institute. 2004;96:1577-1587.
  58. Shim YJ, Doo HK, Ahn SY, Kim YS, Seong JK, Park IS, et al. Inhibitory effect of aqueous extract from the gall of Rhus chinensis on alpha-glucosidase activity and postprandial blood glucose.. Journal of Ethnopharmacology. 2003;85:283-287.
  59. Ao GZ, Zhou MZ, Li YY, Li SN, Wang HN, Wan QW, et al. Discovery of novel curcumin derivatives targeting xanthine oxidase and urate transporter 1 as anti-hyperuricemic agents. Bioorg Med Chem. 2017;25:166-174.
  60. Song HP, Wang H, Liang JX, Qian C, Wu SQ, Xu WJ, et al. Integration of Multiple Analytical and Computational Tools for the Discovery of high-Potency Enzyme inhibitors from herbal medicines. Chem Med Chem. 2016;11:2588-2597.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 1043 Download : 371

Most read articles by the same author(s)